CA3045245A1 - Muscle performance improvement compounds - Google Patents

Muscle performance improvement compounds Download PDF

Info

Publication number
CA3045245A1
CA3045245A1 CA3045245A CA3045245A CA3045245A1 CA 3045245 A1 CA3045245 A1 CA 3045245A1 CA 3045245 A CA3045245 A CA 3045245A CA 3045245 A CA3045245 A CA 3045245A CA 3045245 A1 CA3045245 A1 CA 3045245A1
Authority
CA
Canada
Prior art keywords
nlg3
seq
muscle
actr
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3045245A
Other languages
English (en)
French (fr)
Inventor
Jan Willem Vrijbloed
Marina Maria Boido
Olena BUTENKO
Roberta SCHELLINO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmafox Therapeutics AG
Original Assignee
Pharmafox Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmafox Therapeutics AG filed Critical Pharmafox Therapeutics AG
Publication of CA3045245A1 publication Critical patent/CA3045245A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3045245A 2016-11-29 2017-11-28 Muscle performance improvement compounds Pending CA3045245A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1620119.6A GB201620119D0 (en) 2016-11-29 2016-11-29 Compounds
GB1620119.6 2016-11-29
PCT/IB2017/057436 WO2018100483A1 (en) 2016-11-29 2017-11-28 Muscle performance improvement compounds

Publications (1)

Publication Number Publication Date
CA3045245A1 true CA3045245A1 (en) 2018-06-07

Family

ID=58073474

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3045245A Pending CA3045245A1 (en) 2016-11-29 2017-11-28 Muscle performance improvement compounds

Country Status (11)

Country Link
US (1) US11407799B2 (enExample)
EP (1) EP3548509A1 (enExample)
JP (2) JP7683901B2 (enExample)
KR (1) KR102622245B1 (enExample)
CN (1) CN110036024B (enExample)
AU (1) AU2017367277B2 (enExample)
CA (1) CA3045245A1 (enExample)
GB (1) GB201620119D0 (enExample)
NZ (1) NZ754625A (enExample)
WO (1) WO2018100483A1 (enExample)
ZA (1) ZA201903261B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7051846B2 (ja) 2016-11-10 2022-04-11 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物
JP7258021B2 (ja) 2017-11-09 2023-04-14 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体を含む医薬組成物
KR20200109330A (ko) 2018-01-12 2020-09-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
CA3098679A1 (en) 2018-05-09 2019-11-14 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
EP4081241A4 (en) 2019-12-24 2024-05-01 Juvena Therapeutics, Inc. REGENERATIVE POLYPEPTIDES AND THEIR USES
WO2021189006A1 (en) * 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iia variants
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
US20230257435A1 (en) * 2020-07-24 2023-08-17 Agency For Science, Technology And Research Wound Healing Composition and Uses Thereof
CA3211515A1 (en) * 2021-03-10 2022-09-15 Acceleron Pharma Inc. Actrii-alk4 antagonists and methods of treating heart failure
BR112023018283A2 (pt) * 2021-03-10 2023-10-31 Acceleron Pharma Inc Antagonistas de actrii-alk4 e métodos para tratar insuficiência cardíaca
IL309562A (en) 2021-06-21 2024-02-01 Juvena Therapeutics Inc Regenerative polypeptides and their uses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2174098C (en) * 1993-10-14 2011-01-25 Douglas A. Melton Method of inducing and maintaining neuronal cells
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US7355018B2 (en) * 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
US20060216279A1 (en) 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
EP2056850A4 (en) 2006-08-08 2011-10-12 Univ Louisiana State THERAPEUTIC PROCEDURES FOR NEUROPATHIC PAIN
CA2661836A1 (en) 2006-09-05 2008-03-13 Eli Lilly And Company Anti-myostatin antibodies
KR20160129095A (ko) 2007-02-09 2016-11-08 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
EP3275900A1 (en) 2009-04-27 2018-01-31 Novartis AG Compositions and methods for increasing muscle growth
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
US9676845B2 (en) * 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
EP2295068A1 (en) * 2009-09-04 2011-03-16 Neurotune AG Modified agrin-fragment capable of restoring muscle strength for use as a medicament
WO2011063018A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy

Also Published As

Publication number Publication date
KR102622245B1 (ko) 2024-01-05
KR20190085132A (ko) 2019-07-17
EP3548509A1 (en) 2019-10-09
WO2018100483A1 (en) 2018-06-07
AU2017367277A1 (en) 2019-07-04
JP7683901B2 (ja) 2025-05-27
CN110036024A (zh) 2019-07-19
ZA201903261B (en) 2020-02-26
GB201620119D0 (en) 2017-01-11
AU2017367277B2 (en) 2021-04-01
US20210253654A1 (en) 2021-08-19
JP2019536818A (ja) 2019-12-19
US11407799B2 (en) 2022-08-09
JP2023116479A (ja) 2023-08-22
CN110036024B (zh) 2024-05-07
NZ754625A (en) 2023-03-31

Similar Documents

Publication Publication Date Title
US11407799B2 (en) Muscle performance improvement compounds comprising C-terminus agrin fragment and an ACTR2B inhibitor
EP3816625B1 (en) Compositions and methods for growth factor modulation
JP5801197B2 (ja) 痛みの治療に関する薬剤及び方法
KR102253597B1 (ko) 듀켄씨 근이영양증의 치료에서의 폴리스타틴
JP2009263360A (ja) Ｇｄｎｆリガンドファミリーのメンバーである、アルテミンの新たな使用
CA3049023A1 (en) Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
JP2003530875A (ja) Ｇタンパク質共役型受容体（ｇｐｃｒ）のアゴニストおよびアンタゴニスト、および、それらを用いてｇｐｃｒを活性化および阻害する方法
JP2021502378A (ja) アクチビンＩＩａ型受容体変異体およびそれらの使用方法
AU2002332732B2 (en) Bv8 nucleic acids and polypeptides with mitogenic activity
AU2002332732A1 (en) Bv8 nucleic acids and polypeptides with mitogenic activity
ES2259458T3 (es) Persefina humana.
Zhang et al. NgR acts as an inhibitor to axonal regeneration in adults
HK40115905A (en) Activin receptor type iia variants and methods of use thereof
NZ795003A (en) Muscle performance improvement compounds
Blackmore Neuron-intrinsic limitations to axon regeneration in the developing spinal cord
HK40037556B (en) Activin receptor type iia variants and methods of use thereof
HK40037556A (en) Activin receptor type iia variants and methods of use thereof
HK40039578A (en) Activin receptor type iia variants and methods of use thereof
HK1213804B (zh) 治疗杜兴氏肌营养不良的卵泡抑素
HK1065565B (en) Bv8 nucleic acids and polypeptides with mitogenic activity

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20221103

EEER Examination request

Effective date: 20221103

EEER Examination request

Effective date: 20221103